Can we predict discordant RECIST 1.1 evaluations in double read clinical trials? by Hubert Beaumont, Antoine Iannessi

Get full text

Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us? by Antoine Iannessi, Hubert Beaumont

Get full text

Letter to the editor: “Not all biases are bad: equitable and inequitable biases in machine learning and radiology” by Antoine Iannessi, Hubert Beaumont, Anne Sophie Bertrand

Get full text

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline? by Antoine Iannessi, Hubert Beaumont, Yan Liu, Anne-Sophie Bertrand

Get full text

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials by Hubert Beaumont, Antoine Iannessi, Yi Wang, Charles M. Voyton, Jennifer Cillario, Yan Liu

Get full text

Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response? by Hubert Beaumont, Nathalie Faye, Antoine Iannessi, Emmanuel Chamorey, Catherine Klifa, Chih‐Yi Hsieh

Get full text

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection by Hubert Beaumont, Tracey L. Evans, Catherine Klifa, Ali Guermazi, Sae Rom Hong, Mustapha Chadjaa, Zsuzsanna Monostori

Get full text